The impact of esophagogastric varices on the prognosis of patients with hepatocellular carcinoma

Hsieh, W.-Y.; Chen, Ping‐Hsien; Lin, I-Yen; Su, Chien–Wei; Chao, Yee; Huo, Teh–Ia; Huang, Yi Hsiang; Hou, Ming‐Chih; H, Lin; Wu, Jaw–Ching

doi:10.1038/srep42577

Cited by 28 publications

(28 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most patients with HCC have an underlying advanced chronic liver disease, such as chronic HBV or HCV infection, alcoholism, or nonalcoholic steatohepatitis 17 , 18 . With the progression of liver injury and fibrosis, portal hypertension might develop over time.…”

Section: Introductionmentioning

confidence: 99%

“…*The were 23 (60.5%) and 92 (73.6%) patients with high risk EVs who had EV prophylaxis in SR and RFA groups, respectively (p = 0.179). The presence of EGV, is a surrogate for CSPH and has been validated as an independent factor for poor prognosis among patients with HCC 18,31,32 . Several studies show that the incidence of developing liver decompensation after SR is high among HCC patients with CSPH, which would increase the risk of mortality 24,25,33 (Table 5).…”

mentioning

confidence: 99%

See 1 more Smart Citation

A comparison of prognoses between surgical resection and radiofrequency ablation therapy for patients with hepatocellular carcinoma and esophagogastric varices

Wei

Chau

Chen

et al. 2020

Sci Rep

Self Cite

View full text Add to dashboard Cite

There has been insufficient investigation of the differences in long-term outcomes between surgical resection (SR) and radiofrequency ablation (RFA) among patients with hepatocellular carcinoma (HCC) and esophagogastric varices (EGV). We retrospectively enrolled 251 patients with treatment-naïve HCC and EGV who underwent SR or RFA as a first-line treatment. Prognostic factors were analyzed using a Cox proportional hazards model. A total of 68 patients underwent SR, and the remaining 183 patients received RFA. Patients who underwent SR were younger, had better liver functional reserves, and had larger tumors. After a median follow-up duration of 45.1 months, 151 patients died. The cumulative 5-year overall survival (OS) rate was significantly higher among patients who underwent SR than those treated with RFA (66.7% vs. 36.8%, p < 0.001). Multivariate analysis showed that age > 65 years, multiple tumors, RFA, albumin bilirubin grade > 1, and the occurrence of major peri-procedural morbidity were the independent risk factors that are predictive of poor OS. In conclusion, SR could be recommended as a first-line treatment modality for HCC patients with EGV if the patients are carefully selected and liver function is well preserved.

show abstract

Section: Introductionmentioning

confidence: 99%

mentioning

confidence: 99%

A comparison of prognoses between surgical resection and radiofrequency ablation therapy for patients with hepatocellular carcinoma and esophagogastric varices

Wei

Chau

Chen

et al. 2020

Sci Rep

Self Cite

View full text Add to dashboard Cite

show abstract

“…The majority of patients with HCC have underlying advanced chronic liver disease or even portal hypertension [19], which could make the adoption of treatment strategies and the prediction of outcomes more complex. In addition to the tumor factors, the grade of liver function is also crucial in determining the outcomes of HCC patients, especially of those with early-stage tumor [20].…”

Section: Introductionmentioning

confidence: 99%

The Prognosis of Single Large Hepatocellular Carcinoma Was Distinct from Barcelona Clinic Liver Cancer Stage A or B: The Role of Albumin-Bilirubin Grade

Fang

Kao

et al. 2018

Liver Cancer

Self Cite

View full text Add to dashboard Cite

Background/Aims: Whether single large hepatocellular carcinoma (SLHCC) is classified as Barcelona Clinic Liver Cancer (BCLC) stage A or B is still controversial. We aimed to compare the clinical manifestations, treatment modalities, and prognoses among patients with SLHCC and those in BCLC stage A and B. Methods: We enrolled 2,285 treatment-naive hepatocellular carcinoma (HCC) patients with BCLC stage A or B from October 2007 to December 2015. Factors in terms of prognoses were analyzed by multivariate analysis. Results: We enrolled 1,210, 466, and 609 patients in a BCLC-A, SLHCC, and BCLC-B group, respectively. After a median follow-up duration of 21.2 months, 898 patients had died. The cumulative 5-year survival rates were 57.0, 42.6, and 27.3% for patients in the BCLC-A, SLHCC, and BCLC-B groups, respectively, which were significantly different (p < 0.001). Multivariate analysis indicated that the following independent risk factors were associated with poor prognosis: age > 65 years, alkaline phosphatase > 100 U/L, creatinine > 1.0 mg/dL, alpha-fetoprotein > 20 mg/mL, noncurative treatment, albumin-bilirubin (ALBI) grade, and HCC staging. Subgroup analysis also confirmed that patients in the SLHCC group had a survival rate intermediate to those in the BCLC-A and BCLC-B groups. However, for patients in the SLHCC group and with ALBI grade 1, outcomes were close to those in the BCLC-A group, especially in the setting of curative treatment. For those with ALBI grades 2 or 3, the prognoses were similar to those of the SLHCC and BCLC-B groups. Conclusion: Patients in the SLHCC group had an overall survival rate intermediate to those of the BCLC-A and BCLC-B groups. It is suggested that the SLHCC group could be classified as occupying a different stage from the BCLC stages A and B. The ALBI grade could help to stratify SLHCC into a different prognostic group. However, the results need to be validated externally in other regions of the world.

show abstract

“…In most countries, hepatocellular carcinoma (HCC) represents the traditional surgery to more effective therapies, such as liver transplantation, chemotherapy, radiotherapy, and thermotherapy, the survival rates for HCC are unfortunately poor owing to the high invasive ability of HCC cells [2]. Therefore, it is urgent to explore the genetic mechanisms of HCC and to search for personalized treatment options.…”

Section: Introductionmentioning

confidence: 99%

LncRNA NEAT1 Promotes Deterioration of Hepatocellular Carcinoma Based on In Vitro Experiments, Data Mining, and RT-qPCR Analysis

Ling

Xiong

Meng

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: Accumulated evidence indicates that lncRNA NEAT1 has important roles in various malignant tumors. In this study, we conducted a comprehensive analysis to explore the exact role of NEAT1 in hepatocellular carcinoma (HCC). Methods: The effects of NEAT1 on cell proliferation, apoptosis, migration, and invasion were measured by in vitro experiments. The expression level and clinical value of NEAT1 in HCC was evaluated based on data from The Cancer Genome Atlas (TCGA), Oncomine, and in-house real-time quantitative (RT-qPCR). Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway, and protein-protein interaction (PPI) network analyses were conducted to investigate the potential molecular mechanisms of NEAT1. Results: NEAT1 siRNA not only inhibited proliferation, migration, and invasion of HCC cells but also induced HCC cell apoptosis. A total of four records from TCGA, Oncomine, and RT-qPCR analysis were combined to assess the expression level of NEAT1 in HCC. The pooled standard mean deviation (SMD) indicated that NEAT1 was up-regulated in HCC (SMD = 0.54; 95% CI, 0.36–0.73; P < 0.0001). The area under the curve value of the summary receiver operating characteristic curve was 0.71. NEAT1 expression was also related to race (P = 0.025) and distant metastasis (P = 0.002). Additionally, the results of GO, KEGG pathway, and PPI network analyses suggest that NEAT1 may promote the progression of HCC by interacting with several tumor-related genes (SP1, MDM4, CREBBP, TRAF5, CASP8, TRAF1, KAT2A, and HIST4H4). Conclusions: NEAT1 contributes to the deterioration of HCC and provides a potential biomarker for the diagnosis and therapy of HCC.

show abstract

The impact of esophagogastric varices on the prognosis of patients with hepatocellular carcinoma

Cited by 28 publications

References 44 publications

A comparison of prognoses between surgical resection and radiofrequency ablation therapy for patients with hepatocellular carcinoma and esophagogastric varices

A comparison of prognoses between surgical resection and radiofrequency ablation therapy for patients with hepatocellular carcinoma and esophagogastric varices

The Prognosis of Single Large Hepatocellular Carcinoma Was Distinct from Barcelona Clinic Liver Cancer Stage A or B: The Role of Albumin-Bilirubin Grade

LncRNA NEAT1 Promotes Deterioration of Hepatocellular Carcinoma Based on In Vitro Experiments, Data Mining, and RT-qPCR Analysis

Contact Info

Product

Resources

About